AiCuris GMBH & Co. KG
This article was originally published in Start Up
Executive Summary
With seven molecules in clinical development, another three preclinical compounds approaching the clinic, and a half-dozen discovery programs divided equally between virology and bacteriology, AiCuris is seeking the keys to thwarting viral replication. The start-up has drug candidates targeting herpes simplex virus, human cytomegalovirus and hepatitis C.
You may also be interested in...
Merck Steps Up As AiCuris’ First Development Partner
Merck partners with on AiCuris on letermovir and other antiviral candidates for human cytomegalovirus (HCMV), marking the first development deal for the German drug developer, spun out from Bayer in 2006.
Start-Up Previews (11/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Look For A Place In Coming Hepatitis C Combo Regimens." features profiles of AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus. Plus these Start-Ups Across Health Care: Arineta, HemoShear, Hygieia and Silver Bullet Therapeutics.
Start-Ups Look For Places In Future HCV Combo Regimens
With more than 50 drugs in development for hepatitis C, what comes next after first-generation protease inhibitors and what opportunity might there be for small start-up firms in a space where so many Big Pharma and specialty pharma companies are active? Approvals of direct-acting antiviral therapies are just around the corner in hepatitis C, and smaller companies are looking to provide parts of the puzzle in next-generation drug cocktails that will tackle the growing disease. However, in order for small companies to succeed in this highly competitive space they'll need highly differentiated products. START-UP profiles AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus.